Your browser doesn't support javascript.
loading
Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.
Kast, Karin; John, Esther M; Hopper, John L; Andrieu, Nadine; Noguès, Catherine; Mouret-Fourme, Emmanuelle; Lasset, Christine; Fricker, Jean-Pierre; Berthet, Pascaline; Mari, Véronique; Salle, Lucie; Schmidt, Marjanka K; Ausems, Margreet G E M; Garcia, Encarnacion B Gomez; van de Beek, Irma; Wevers, Marijke R; Evans, D Gareth; Tischkowitz, Marc; Lalloo, Fiona; Cook, Jackie; Izatt, Louise; Tripathi, Vishakha; Snape, Katie; Musgrave, Hannah; Sharif, Saba; Murray, Jennie; Colonna, Sarah V; Andrulis, Irene L; Daly, Mary B; Southey, Melissa C; de la Hoya, Miguel; Osorio, Ana; Foretova, Lenka; Berkova, Dita; Gerdes, Anne-Marie; Olah, Edith; Jakubowska, Anna; Singer, Christian F; Tan, Yen; Augustinsson, Annelie; Rantala, Johanna; Simard, Jacques; Schmutzler, Rita K; Milne, Roger L; Phillips, Kelly-Anne; Terry, Mary Beth; Goldgar, David; van Leeuwen, Flora E; Mooij, Thea M; Antoniou, Antonis C.
Afiliación
  • Kast K; Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany. karin.kast@uk-koeln.de.
  • John EM; Department of Epidemiology & Population Health and of Medicine (Oncology), Stanford University School of Medicine, Stanford, CA, USA.
  • Hopper JL; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Andrieu N; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Noguès C; INSERM U900, Paris, France.
  • Mouret-Fourme E; Institut Curie, Paris, France.
  • Lasset C; Mines Paris Tech, Fontainebleau, France.
  • Fricker JP; PSL Research University, Paris, France.
  • Berthet P; Aix Marseille Université, INSERM, IRD, SESSTIM, Marseille, France.
  • Mari V; Département d'Anticipation et de Suivi Des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, Marseille, France.
  • Salle L; Institut Curie, Paris, France.
  • Schmidt MK; Centre Léon Bérard, Lyon, France.
  • Ausems MGEM; CRLCC Paul Strauss, Strasbourg, France.
  • Garcia EBG; Centre François Baclesse, Caen, France.
  • van de Beek I; Centre Antoine Lacassagne, Nice, France.
  • Wevers MR; Oncogénétique Poitou-Charentes, Niort, France.
  • Evans DG; Division of Molecular Pathology, Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Tischkowitz M; Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Lalloo F; Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Cook J; Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Izatt L; Department of Clinical Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Tripathi V; The Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Snape K; Genomic Medicine, Division of Evolution and Genomic Sciences, The University of Manchester, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
  • Musgrave H; Manchester Breast Centre, Oglesby Cancer Research Centre, The Christie, University of Manchester, Manchester, UK.
  • Sharif S; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
  • Murray J; Clinical Genetics Service, Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Colonna SV; Department of Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Andrulis IL; Clinical Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Daly MB; Department of Clinical Genetics, St George's University Hospitals NHS Foundation Trust, London, UK.
  • Southey MC; Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • de la Hoya M; West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Edgbaston, Birmingham, UK.
  • Osorio A; Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Foretova L; West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Edgbaston, Birmingham, UK.
  • Berkova D; South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, UK.
  • Gerdes AM; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Jakubowska A; Department of Medicine and Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.
  • Singer CF; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
  • Tan Y; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Augustinsson A; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Rantala J; Precision Medicine, School of Clinical Sciences at, Monash Health Monash University, Clayton, VIC, Australia.
  • Simard J; Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia.
  • Schmutzler RK; Molecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.
  • Milne RL; Familial Cancer Clinical Unit, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO) and Spanish Network On Rare Diseases (CIBERER), Madrid, Spain.
  • Phillips KA; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Terry MB; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Goldgar D; Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • van Leeuwen FE; Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
  • Mooij TM; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Antoniou AC; Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.
Breast Cancer Res ; 25(1): 72, 2023 06 20.
Article en En | MEDLINE | ID: mdl-37340476
INTRODUCTION: Height, body mass index (BMI), and weight gain are associated with breast cancer risk in the general population. It is unclear whether these associations also exist for carriers of pathogenic variants in the BRCA1 or BRCA2 genes. PATIENTS AND METHODS: An international pooled cohort of 8091 BRCA1/2 variant carriers was used for retrospective and prospective analyses separately for premenopausal and postmenopausal women. Cox regression was used to estimate breast cancer risk associations with height, BMI, and weight change. RESULTS: In the retrospective analysis, taller height was associated with risk of premenopausal breast cancer for BRCA2 variant carriers (HR 1.20 per 10 cm increase, 95% CI 1.04-1.38). Higher young-adult BMI was associated with lower premenopausal breast cancer risk for both BRCA1 (HR 0.75 per 5 kg/m2, 95% CI 0.66-0.84) and BRCA2 (HR 0.76, 95% CI 0.65-0.89) variant carriers in the retrospective analysis, with consistent, though not statistically significant, findings from the prospective analysis. In the prospective analysis, higher BMI and adult weight gain were associated with higher postmenopausal breast cancer risk for BRCA1 carriers (HR 1.20 per 5 kg/m2, 95% CI 1.02-1.42; and HR 1.10 per 5 kg weight gain, 95% CI 1.01-1.19, respectively). CONCLUSION: Anthropometric measures are associated with breast cancer risk for BRCA1 and BRCA2 variant carriers, with relative risk estimates that are generally consistent with those for women from the general population.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Genes BRCA2 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Breast Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Genes BRCA2 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Breast Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido